4 years ago

Quell Therapeutics Raises £60.4M for Engineered Treg Cell Therapies

  • Quell Therapeutics Ltd, a biotech company, has raised £60.4M in Series A funding to progress its engineered T regulatory cell therapies for liver transplantation, autoimmune, and neuroinflammatory diseases.

      • ProblemHealthcare

      "Patients who receive organ transplants, such as liver transplants, require lifelong immunosuppressive medication to prevent their bodies from rejecting the new organ. These medications have serious side effects and don't always prevent rejection. "

      Solution

      "Quell Therapeutics is developing genetically engineered T regulatory (Treg) cell therapies. These therapies work by harnessing the body's natural immune system to suppress the immune response that leads to organ rejection. This could potentially eliminate the need for lifelong immunosuppressive drugs and improve the lives of transplant patients."

      Covered on